Table of Contents Author Guidelines Submit a Manuscript
Mediators of Inflammation
Volume 2006, Article ID 38458, 6 pages
http://dx.doi.org/10.1155/MI/2006/38458
Research Communication

Serum Levels of Tissue Inhibitors of Metalloproteinase 2 in Patients With Systemic Sclerosis With Duration More Than 2 Years: Correlation With Cardiac and Pulmonary Abnormalities

1Rheumatology and Rehabilitation Department, Faculty of Medicine, Cairo University, Cairo, Egypt
2Dermatology Department, Faculty of Medicine, Cairo University, Cairo, Egypt
3Medical Biochemistry Department, Faculty of Medicine, Cairo University, Cairo, Egypt
4Internal Medicine Department, Faculty of Medicine, Cairo University, Cairo, Egypt
5Medical Biochemistry Department, Faculty of Pharmacy, Cairo University, Cairo, Egypt

Received 21 July 2006; Revised 15 October 2006; Accepted 15 October 2006

Copyright © 2006 Amira Shahin et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

In this study, we measured the serum concentration of TIMP-2 in patients with systemic sclerosis (SSc) and explored its possible correlation with cardiac and pulmonary lesions. We studied 42 patients with SSc, with duration equal to or more than 2 years. CT chest, ECG, echocardiography, and serum TIMP-2 concentration measurement using ELISA technique were performed in all patients and in 25 normal controls. The mean serum levels of TIMP-2 in patients was higher than in controls (P=.005). The mean CT score of dSSc patients with elevated TIMP-2 levels was significantly higher than dSSc patients with normal levels (P=.013). Four patients out of five with elevated TIMP-2 levels showed diastolic dysfunction (80%), compared to 2 out of 15 lSSc patients with normal levels (13.3%), with P=.014. Our research, though involving a small group of patients, points to the probable role of TIMP-2 in the development of pulmonary lesions in dSSc patients and cardiac lesions in lSSc patients with duration equal to or more than 2 years.